Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Bayer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 45596) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 07:44pm CET

TIME: 8:30 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 45596) holds a meeting of the Antimicrobial Drugs Advisory Committee to discuss new drug application 209367, ciprofloxacin inhalation powder, sponsored by Bayer HealthCare Pharmaceuticals, Inc., for the proposed indication of reduction of exacerbations in non-cystic fibrosis bronchiectasis adult patients with respiratory bacterial pathogens.

DATE: November 16, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Lauren Tesh, 301-796-9001, [email protected]

Copyright (c) 2017 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
03:22a BAYER : Patent Issued for Fluid Mixing Control Device for a Multi-Fluid Delivery..
01/17 BAYERNPV : Bayer - FDA report reaffirms safety profile and effectiveness of Baye..
01/17 BAYER CROPSCIENCE : confident of CCI approval for $66-Monsanto deal by May 2018
01/11 Bayer raises higher than expected 1.8 billion euros from Covestro placement
01/11 BAYER : Reduces Direct Stake in Covestro to 14.2%
01/11 BAYER : sells 10.4 percent stake in Covestro
01/10 Bayer to sell Covestro shares worth about $1.8 billion
01/10 BAYER : Further Reduces Stake in Covestro
01/10 BAYER : further reduces holding in Covestro
01/10 Bayer, J&J win reversal of US$28 million verdict in Xarelto lawsuit
More news
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 Investors unmoved by Exelixis' late-stage liver cancer data on cabozantinib; ..
01/16 Greenlight Capital's (David Einhorn) Q4 2017 Letter
01/15 ROAD TO FINANCIAL INDEPENDENCE : My December 88-Stock Portfolio Review
01/11 Bayer sells 10.4% stake in Covestro, raising ?1.8B
Financials (€)
Sales 2017 36 021 M
EBIT 2017 7 681 M
Net income 2017 6 560 M
Debt 2017 8 995 M
Yield 2017 2,53%
P/E ratio 2017 13,86
P/E ratio 2018 18,67
EV / Sales 2017 2,63x
EV / Sales 2018 2,42x
Capitalization 85 672 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 121 €
Spread / Average Target 17%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-0.38%105 827
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287